Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Revive Therapeutics Ltd (OP:RVVTF)

0.0219 UNCHANGED
Streaming Delayed Price Updated: 1:20 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revive Therapeutics Ltd

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin... 
Via Benzinga
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to... 
Via Benzinga
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
From Revive Therapeutics Ltd.
Via GlobeNewswire
Meth Use Disorder Tackled With Psilocybin: Clinical Trial Begins Patient Enrollment
Life sciences company Revive Therapeutics Ltd. 
Via Benzinga
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
First subject enrolled and initial top-line results expected in Q3-2023 
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More 
Via Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve 
Via Benzinga
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items. 
Via Benzinga
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January. 
Via Benzinga
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders
Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.< 
Via Benzinga
Revive Therapeutics Ltd. Closes $4.3 Million Offering
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.